Fig. 4From: Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA projectBoxplot comparing the new biomarkers before the switch and after two years of treatment in patients previously treated with miglustat or ERT. Graphical representation of the mean results for the new biomarkers before eliglustat treatment and after two years A CCL18/PARC concentration; B YKL-40 concentration; C Lipocalin-2 concentration. *p value < 0.05; **p value < 0.01Back to article page